Early postoperative thrombosis of an aortic bioprosthetic valve: Should anticoagulation be patient specific?

Journal of Cardiac Surgery

Volumn 28, Issue 6, 2013, Pages 723-729

  Efthymiou, Christopher Andrew ^a   Mills, Rosalind Jane ^a   O'Regan, David John ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

AGE; ANTICOAGULANT THERAPY; AORTA STENOSIS; AORTA VALVE PROSTHESIS; AORTA VALVE REPLACEMENT; BRAIN ISCHEMIA; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; HEART LEFT VENTRICLE FUNCTION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; META ANALYSIS; MULTICENTER STUDY (TOPIC); NONHUMAN; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE PERIOD; POSTOPERATIVE THROMBOSIS; PRACTICE GUIDELINE; PREOPERATIVE PERIOD; PROSTHETIC VALVE THROMBOSIS; PROTHROMBIN TIME; REOPERATION; REVIEW; SHORT STATURE; SMOKING; SURVIVAL; SYSTOLIC HEART MURMUR; THROMBOGENICITY; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; AORTIC VALVE; AORTIC VALVE STENOSIS; ASPIRIN; BIOPROSTHESIS; FIBRINOLYTIC AGENTS; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; META-ANALYSIS AS TOPIC; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; PROSTHESIS FAILURE; REOPERATION; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84887623343     PISSN: 08860440     EISSN: 15408191     Source Type: Journal    
DOI: 10.1111/jocs.12181     Document Type: Review

References (20)

1. Bridgewater B, Keogh B, Kinsman R, et al. Sixth National Adult Cardiac Surgical Database Report 2008. Dendrite Clinical Systems Ltd, Oxfordshire, 2008.
2. Brennan JM, Edwards FH, Zhao Y, et al. Long-term safety and effectiveness of mechanical versus biologic aortic valve prostheses in older patients: Results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. Circulation 2013; 127 (16): 1647-1655.
3. Celiento M, Ravenni G, Milano AD, et al. Aortic valve replacement with the Medtronic Mosaic bioprosthesis: A 13-year follow-up. Ann Thorac Surg 2012; 93 (2): 510-515.
4. Pellerin M, Mihaileanu S, Couëtil JP, et al. Carpentier-Edwards pericardial bioprosthesis in aortic position: Long-term follow-up 1980 to 1994. Ann Thorac Surg 1995; 60 (2 Suppl): S292-S295.
5. Bonow RO, Carabello BA, Chatterjee K, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 52 (13): e1-e142.
6. Stein PD, Alpert JS, Bussey HI, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001; 119: 220S-227S.
7. Butchart EG, Gohlke-Bärwolf C, Antunes MJ, et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005; 26 (22): 2463-2471.
8. Brown ML, Park SJ, Sundt TM, et al. Early thrombosis risk in patients with biologic valves in the aortic position. J Thorac Cardiovasc Surg 2012; 144 (1): 108-111.
9. ElBardissi AW, DiBardino DJ, Chen FY, et al. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm ? J Thorac Cardiovasc Surg 2010; 139 (5): 1137-1145.
10. di Marco F, Grendene S, Feltrin G, et al. Antiplatelet therapy in patients receiving aortic bioprostheses: A report of clinical and instrumental safety. J Thorac Cardiovasc Surg. 2007; 133 (6): 1597-1603.
11. Sundt TM, Zehr KJ, Dearani JA, et al. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement ? J Thorac Cardiovasc Surg 2005; 129 (5): 1024-1031.
12. Brueck M, Kramer W, Vogt P, et al. Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors. Eur J Cardiothorac Surg 2007; 32 (1): 108-112.
13. Aramendi JI, Mestres CA, Martinez-Leõn J, et al. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): Prospective, randomized, co-operative trial. Eur J Cardiothorac Surg 2005; 27 (5): 854-860.
14. Colli A, Verhoye JP, Heijmen R, et al. for the ACTION Investigators. Low-dose acetyl salicylic acid versus oral anticoagulation after bioprosthetic aortic valve replacement. Final report of the ACTION registry. Int J Cardiol 2012; S0167-5273 (12): 01539-2.
15. Mérie C, Køber L, Skov Olsen P, et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, bleeding. JAMA 2012; 308 (20): 2118-2125.
16. Gherli T, Colli A, Fragnito C, et al. Comparing warfarin with aspirin after biological aortic valve replacement: A prospective study. Circulation 2004; 110 (5): 496-500.
17. Jamieson WR, Moffatt-Bruce SD, Skarsgard P, et al. Early antithrombotic therapy for aortic valve bioprostheses: Is there an indication for routine use ? Ann Thorac Surg 2007; 83 (2): 549-556.
18. Efthymiou C, Kaiche R, Pillai R:, Endothelialisation of an autologous pericardial valve implanted in the aortic position. Heart 2006; 92 (11): 1627.
19. Puvimanasinghe JP, Steyerberg EW, Takkenberg JJ, et al. Prognosis after aortic valve replacement with a bioprosthesis: Predictions based on meta-analysis and microsimulation. Circulation 2001; 103 (11): 1535-1541.
20. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285 (22): 2864-2870.